Spermosens

Changes in shareholding over 5%:

• Nordnet Bank AB has acquired 159,160,436 shares, representing 12.09% of the voting rights and capital.
• Michael Kantor has acquired 93,368,016 shares, corresponding to 7.01% of the voting rights and capital.
• Henrik Jensen has increased his holding from 9,741,090 shares (3.43%) to 91,200,461 shares, now representing 6.93% of the voting rights and capital.
• FlexMedical Solutions Ltd has increased their holding from 9,274,174 shares (3,27%) to 83,227,374 shares, amounting to 6.32% of the voting rights and capital.

The updated list of the company’s major shareholders will soon be available on Spermosens.com

For further information, please contact:
Tore Duvold, CEO
Email: info@spermosens.com

Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checkedproduct aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market. The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com